Kazia Therapeutics (NASDAQ: KZIA) appoints James Levine as new CFO
Rhea-AI Filing Summary
Kazia Therapeutics Limited has appointed James Levine as Chief Financial Officer, effective June 1, 2026. Under his employment agreement, he will receive an annual base salary of US$475,000, an annual target bonus equal to 40% of base salary (prorated for 2026), and options over 200,000 American Depositary Shares.
One-third of the options vest at the start of employment, with the rest vesting in equal yearly installments, and all options are forfeited if he leaves voluntarily within the first year. If his role ends without cause or he resigns for good reason, he may receive up to 12 months’ salary and health coverage in certain change-in-control situations, or up to 6 months’ salary and health coverage otherwise, subject to conditions including a release of claims.
Positive
- None.
Negative
- None.
Key Figures
CFO base salary: US$475,000 per year
Target bonus: 40% of base salary
Equity options grant: 200,000 ADS options
+4 more
7 metrics
CFO base salary
US$475,000 per year
Annual base salary for James Levine as CFO
Target bonus
40% of base salary
Annual target bonus opportunity, prorated for 2026
Equity options grant
200,000 ADS options
Subject to Board approval for new CFO
Change-in-control severance
12 months base salary
Severance for termination without cause or for good reason in change in control
Standard severance cap
Up to 6 months base salary
Termination without cause or for good reason outside change in control
COBRA health coverage
Up to 6 months
Continued healthcare coverage following eligible termination
Non-solicitation period
12 months
Post-termination non-solicitation covenant in Employment Agreement
Key Terms
Change in Control, Good Reason, Orphan Drug Designation, Fast Track Designation, +2 more
6 terms
Change in Control financial
"In the event of a termination without Cause or resignation for Good Reason ... in connection with a Change in Control"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
Good Reason financial
"In the event of a termination without Cause or resignation for Good Reason (each as defined in the Employment Agreement)"
Orphan Drug Designation regulatory
"Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S. Food and Drug Administration"
Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.
Fast Track Designation regulatory
"Paxalisib was also granted FTD in July 2023 for the treatment of solid tumor brain metastases"
Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.
Rare Pediatric Disease Designation regulatory
"Additionally, paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA"
A rare pediatric disease designation is an official regulatory status given to a drug or therapy that targets a serious or life‑threatening condition primarily affecting children and is uncommon in the population. It matters to investors because the status often brings financial and development perks — such as tax credits, reduced fees, faster review and periods of market protection — which can lower costs, speed approval and improve the commercial outlook; think of it as a VIP pass that makes bringing a scarce, child‑focused treatment to market easier and potentially more profitable.
non-solicitation covenant financial
"a 12-month post-termination non-solicitation covenant"
A non-solicitation covenant is a contract clause that stops one party from actively recruiting or doing business with the other party’s employees, customers or suppliers for a set time. Think of it as a temporary “do not lure” rule that protects relationships and team members after a deal or employment change. For investors, it reduces the risk that key staff or clients will be poached, helping protect revenue, integration plans and the value of the investment.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What executive change did Kazia Therapeutics (KZIA) announce in this Form 6-K?
Kazia Therapeutics appointed James Levine as Chief Financial Officer, effective June 1, 2026. The filing outlines his compensation package, equity incentives, severance protections, and related terms in an employment agreement between Kazia Therapeutics, Inc. and Mr. Levine.
What is the base salary and bonus opportunity for Kazia Therapeutics’ new CFO?
James Levine will receive an annual base salary of US$475,000 and is eligible for a target annual bonus equal to 40% of his base salary. The bonus for 2026 will be prorated based on his June 1, 2026 start date.
How many equity options is the new Kazia (KZIA) CFO expected to receive and how do they vest?
Subject to Board approval, James Levine will be granted options over 200,000 ADSs. One-third of these options vest upon commencement of employment, while the remaining two-thirds vest in equal yearly installments thereafter, with forfeiture if he leaves voluntarily within one year.
What severance benefits can Kazia’s CFO receive upon termination?
If terminated without cause or resigning for good reason in connection with a change in control, he may receive 12 months of base salary, a pro-rata bonus, and up to 6 months of COBRA coverage. Outside a change in control, salary severance is up to 6 months, subject to mitigation.
Does the Kazia Therapeutics CFO agreement include non-solicitation or confidentiality covenants?
Yes. The agreement includes confidentiality and assignment of inventions provisions, plus a 12‑month post‑termination non-solicitation covenant. Receipt of severance benefits also requires compliance with confidentiality and proprietary information obligations and signing a general release of claims.
What are the key conditions for the Kazia (KZIA) CFO to receive severance benefits?
Severance is conditioned on his termination meeting defined criteria, such as without cause or for good reason, plus his compliance with confidentiality and proprietary information agreements and delivery of an effective general release of claims within 30 days following termination.